Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C D Collins

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
European Journal of Nuclear Medicine|March 18, 1999
Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia?R A Cooper, R A Cowan, S E Owens, et al.
Neurogenetics|April 30, 2013
Peripheral blood gene expression signature differentiates children with autism from unaffected siblingsS W Kong, Y Shimizu-Motohashi, M G Campbell, et al.
Cancer Chemotherapy and Pharmacology|April 28, 2006
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancerR O'Connor, M O'Leary, J Ballot, et al.
Irish Medical Journal|June 15, 2007
Sentinel lymph node biopsy in elderly irish patients with malignant melanomaD E Moran, M J Smith, M J O'Sullivan, et al.
Vascular Pharmacology|October 13, 2006
The application of genomic and proteomic technologies in predictive, preventive and personalized medicineC D Collins, S Purohit, R H Podolsky, et al.
Acta Oncologica (Stockholm, Sweden)|February 9, 2018
(ICORG 05-03): prospective randomized non-inferiority phase III trial comparing two radiation schedules in malignant spinal cord compression (not proceeding with surgical decompression); the quality of life analysisK A Lee, M Dunne, C Small, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 4, 2017
A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung CancerD N Cagney, P G Thirion, M T Dunne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancerA Weaver, J Chang, E Wrigley, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
European Journal of Nuclear Medicine|March 18, 1999
Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia?R A Cooper, R A Cowan, S E Owens, et al.
Neurogenetics|April 30, 2013
Peripheral blood gene expression signature differentiates children with autism from unaffected siblingsS W Kong, Y Shimizu-Motohashi, M G Campbell, et al.
Cancer Chemotherapy and Pharmacology|April 28, 2006
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancerR O'Connor, M O'Leary, J Ballot, et al.
Irish Medical Journal|June 15, 2007
Sentinel lymph node biopsy in elderly irish patients with malignant melanomaD E Moran, M J Smith, M J O'Sullivan, et al.
Vascular Pharmacology|October 13, 2006
The application of genomic and proteomic technologies in predictive, preventive and personalized medicineC D Collins, S Purohit, R H Podolsky, et al.
Acta Oncologica (Stockholm, Sweden)|February 9, 2018
(ICORG 05-03): prospective randomized non-inferiority phase III trial comparing two radiation schedules in malignant spinal cord compression (not proceeding with surgical decompression); the quality of life analysisK A Lee, M Dunne, C Small, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 4, 2017
A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung CancerD N Cagney, P G Thirion, M T Dunne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancerA Weaver, J Chang, E Wrigley, et al.
Pageof 11